Data from phase III ENERGITO study of Stiolto Respimat (olodaterol + tiotropium) published in journal of chronic obstructive pulmonary disease- Boehringer
Boehringer has announced the publication of data that show Stiolto Respimat (olodaterol + tiotropium) improved lung function across a range of measures (FEV1 AUC0–12, FEV1 AUC0–24, FEV1 AUC12–24, peak0-3 FEV1 and trough FEV1) in patients with chronic obstructive pulmonary disease (COPD), compared to a European formulation of a combination of a long-acting beta agonist (LABA), salmeterol, and an inhaled corticosteroid (ICS), fluticasone propionate (50/500 mcg, 50/250 mcg). Published online in Journal of Chronic Obstructive Pulmonary Disease, these data are from the ENERGITO study, which investigated the impact of Stiolto Respimat on lung function among moderate to severe COPD patients.
In the six week ENERGITO multicenter complete crossover study (NCT01969721), patients treated with once-daily Stiolto Respimat had significant increases in FEV1 AUC0-12, the primary endpoint, than patients treated with salmeterol/fluticasone propionate (T+O 5/5 mcg compared to salmeterol/fluticasone propionate 50/500 mcg: 129mL and 50/250 mcg: 125mL. In the study, FEV1 AUC0-24, the key secondary endpoint, was also significantly increased with Stiolto Respimat after six weeks compared to salmeterol/fluticasone propionate (T+O 5/5 mcg compared to salmeterol/fluticasone propionate 50/500 mcg: 86 mL and 50/250 mcg: 82 mL. Stiolto Respimat also increased lung function compared to salmeterol/fluticasone propionate as measured by the following additional secondary endpoints at week six.
The frequency of adverse events (AEs) was similar between all treatment groups with 29.7-37.0 percent of patients reporting at least one AE while on treatment. The most common adverse reactions were nasopharyngitis (common cold), COPD and cough.
The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.
Related news and insights
Eli Lilly and Company and Incyte announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA).
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.
Mirati Therapeutics announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for MRTX 849 (adagrasib) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.